Serviço de Nefrologia, Centro Hospitalar Universitário do Algarve, Faro, Portugal; Algarve Biomedical Center, Faro, Portugal
Perit Dial Int. 2019 May-Jun;39(3):201-209. doi: 10.3747/pdi.2018.00138.
Peritoneal protein loss (PPL) through peritoneal effluent has been a well-recognized detrimental result of peritoneal dialysis (PD) treatment since its inception. Investigation has focused mainly on PPL quantitative and qualitative determinations and evaluation of its prognostic value.A comprehensive review of the pathophysiology of PPL (3-pore model revisited), methods of quantification, dialysate protein composition, and impact on clinical outcomes is presented herein. The author summarizes a brief analysis of associated cardiovascular disease and nutritional consequences, exploring the controversial cause-effect on mortality and technique failure.Therapeutic modalities aiming to reduce PPL (angiotensin-converting enzyme inhibitors [ACEI]s and vitamin D therapies) were explored, although it is unclear whether PPL represents a valid therapeutic target or, on the other hand, is solely a manifestation of endothelial dysfunction.
腹膜蛋白丢失(PPL)通过腹腔流出液一直是腹膜透析(PD)治疗中公认的有害结果,自 PD 治疗开展以来,人们一直主要关注 PPL 的定量和定性测定及其预后价值的评估。本文全面回顾了 PPL 的病理生理学(重新审视 3 孔模型)、定量方法、透析液蛋白组成以及对临床结果的影响。作者简要分析了相关心血管疾病和营养后果,探讨了其对死亡率和技术失败的因果关系的争议。本文还探讨了旨在减少 PPL 的治疗方法(血管紧张素转换酶抑制剂 [ACEI] 和维生素 D 治疗),尽管尚不清楚 PPL 是否代表一个有效的治疗靶点,或者它是否仅仅是内皮功能障碍的一种表现。